A+ A A-


2018歐洲腫瘤內科學會年會(ESMO)8大亮點研究報告 即將公布


1. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab- P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
Speakers:Peter Schmid (London, GB)
報告時間:2018年10月20日 16:30-16:45

2. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3
在荷爾蒙受體陽性(HR +),人類表皮生長因子受體2-陰性(HER2-)晚期乳癌的女性中使用palbociclib加fulvestrant的總生存期:來自PALOMA-3的分析
Speakers: Massimo Cristofanilli (Chicago, US)
報告時間:2018年10月20日 17:00-17:15

3. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial
Alpelisib(ALP)+ fulvestrant(FUL)用於晚期乳癌:第3階段SOLAR-1臨床試驗的結果
Speakers: Fabrice André (Villejuif, FR)

4. Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer
Abiraterone Acetate加Prednisone與Prednisolone單用對於高危險族群和低危險族群轉移性荷爾蒙敏感性前列腺癌的影響
Speakers :Alex P. Hoyle (Manchester, GB)
報告時間:2018年10月21日 16:30-16:45

5. Radiotherapy (RT) to the primary tumour for men with newly- diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476)
Speakers :Chris C. Parker (Sutton, GB)

6. JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
JAVELIN Renal 101:avelumab + axitinib vs sunitinib作為晚期腎細胞癌(aRCC)第一線治療的隨機3期研究
Speakers: Robert J. Motzer (New York, US)

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
在晚期卵巢癌和BRCA1 / 2突變(BRCAm)的新診斷患者中進行鉑類化療後用olaparib維持治療:第三期試驗SOLO1
Speakers :Kathleen N. Moore (Oklahoma City, US)
報告時間:2018年10月21日 17:45-18:00

7. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
KEYNOTE-048:第一線使用pembrolizumab治療復發/轉移性頭頸部鱗狀細胞癌(R / M HNSCC)的第3期研究
Speakers: Barbara Burtness (New Haven, US)
報告時間:2018年10月22日 16:30-16:45

8. Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy
Speakers: Hisham Mehanna (Birmingham, GB)
報告時間:2018年10月22日 17:00-17:15